Clinical Efficacy And Adverse Reactions Of Apatinib In Patients With Advanced Breast Cancer

Objective: By using the path for the treatment of patients with advanced breast cancer,analysis after treatment in patients with therapeutic effect and adverse reaction of occurrence,in order to explore the path for therapeutic value in patients with advanced breast cancer,and for its future application in the clinical to provide effective basis.Methods: The study selected 58 patients with advanced breast cancer from January 2015 to January 2016 in the Oncology Department of the People’s Hospital of Tengzhou City as the subjects of study.All patients were grouped by random number table method,29 in the experimental group and 29 in the control group.The experimental group used methanate apatinil for treatment,and the control group used tigio for treatment.The treatment effect,adverse reaction occurrence,survival rate,and tumor marker level and quality of life before and after treatment were compared between the two groups.Results: There was no statistically significant difference between the two groups in age,postmenopausal status,lymph node metastasis,ER and PR(P BBB 0.05).Only one patient in the study group was completely relieved after treatment,but the total effective rate was 93.10%,significantly higher than 68.97% in the control group(P < 0.05).Within the team a total of 3 patients appeared adverse reaction,the incidence of adverse reactions was 10.34%,while in the control group a total of 11 patients appeared adverse reaction,the incidence of adverse reactions was 37.93%,the team was significantly lower than control group(P < 0.05);Compared two groups of patients before treatment levels of tumor markers there was no statistically significant difference(P > 0.05),after treatment,two groups of patients with all levels of tumor markers were significantly lower,significantly lower than before treatment(P < 0.05),and the team obviously lower than the control group(P < 0.05);There was no statistically significant difference between the two groups before and after treatment(P < 0.05).There was no significant difference in survival rates between the two groups after 3 months and 6 months of treatment(P>0.05),while the survival rates at 12 months,18 months,and 24 months after treatment in the study group were79.31%,65.52% and 58.62% were significantly higher than the control group(P<0.05);The quality of life of the study group was 89.66%,significantly higher than the control group’s 55.17%,and the difference was statistically significant(P < 0.05).Conclusion: Breast cancer types as a common malignant tumor in clinical disease,through the chemotherapy treatment on the basis of using the path for the treatment of patients with advanced breast cancer,can effectively improve the therapeutic effect of patients,and the relatively low incidence of adverse reactions,to improve patients’ quality of life and long-term survival,should be widely used and promoted.